Placenta extract in the treatment of androgenetic hair loss
Phase 1
Recruiting
- Conditions
- Androgenic alopecia.Androgenic alopecia
- Registration Number
- IRCT20210612051545N5
- Lead Sponsor
- Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Male
- Target Recruitment
- 30
Inclusion Criteria
Patients with androgenetic alopecia
Age 18 to 50 years
Male
Norwood-Hamilton grade II to V
Exclusion Criteria
Patients with two or more diagnoses of hair loss
Treatment of hair loss in the last 3 months
Patients undergoing radiotherapy and chemotherapy
Immunosuppressive drugs or corticosteroids during the previous 4 weeks
Uncontrolled chronic diseases
Malignancy
Coagulopathy or the use of anticoagulants
History of autoimmune diseases
HBV, HCV and HIV infections
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Side effects. Timepoint: zero and 2 weeks, 1, 2, 4 and 6 months after first injection. Method of measurement: History and clinical examination based on Common Terminology Criteria for Adverse Events criteria.
- Secondary Outcome Measures
Name Time Method Frontal and vertex hair density. Timepoint: 1, 2, 4, and 6 months after the first injection. Method of measurement: Digital videotrichoscopy.